1616760-97-4

Basic information

• Product Name: Tofacitinib Impurity 2
• Synonyms: Tofacitinib-30;Tofacitinib Imp.E;Tofatinib Impurity E;Azilsartan medoxomil impurity327;N-((3R,4R)-4-methyl-piperidin-3-yl)-N-methyl-2-chloro-7H-pyrrolo[2,3-D]pyrimidine-4-amine;7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 2-chloro-N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]-;Tofacitinib impurity 5/2-chloro-N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo [2,3-d]pyrimidin-4-amine
• CAS NO: 1616760-97-4
• Molecular Formula: C13H18ClN5
• Molecular Weight: 279.77
• Mol File: 1616760-97-4.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Tofacitinib Impurity 2(CAS DataBase Reference)
• NIST Chemistry Reference: Tofacitinib Impurity 2(1616760-97-4)
• EPA Substance Registry System: Tofacitinib Impurity 2(1616760-97-4)

Safety Data

• Hazardous Substances Data: 1616760-97-4(Hazardous Substances Data)

Usage

General Description

"Tofacitinib Impurity 2" is a chemical compound that is used as an impurity in the production of the drug tofacitinib. It is also known by the chemical name 3,4-dimethylisothiazole. Tofacitinib Impurity 2 is an intermediate in the synthesis of tofacitinib and must be carefully monitored and controlled during the manufacturing process to ensure the purity and quality of the final drug product. Impurities like Tofacitinib Impurity 2 can affect the safety and effectiveness of the medication, so strict regulations and quality control measures are in place to ensure that only trace amounts of impurities are present in the final drug formulation.

Upstream product

• 1616760-91-8 methyl-(1-trityl-4-methylpiperidin-3-yl)carbamate 
• 1616833-40-9 1-triryI-N,4-dimethylpiperidin-3-amine 
• 1616760-93-0 (3R,4R)-1-trityl-N,4-dimethylpiperidin-3-amine 
• 934524-10-4 2,4-dichloro-7-p-methylbenzenesulfonyl-7H-pyrrole[2,3-d]pyrimidin-4-amine 
• 90213-66-4 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine 
• 1616760-94-1 C₃₉H₃₈ClN₅O₂S 
• 1616760-95-2 C₂₀H₂₄ClN₅O₂S 
• 1616760-96-3 C₃₂H₃₂ClN₅ 
• 694495-63-1 O-methyl-N-(4-methylpyridin-3-yl)carbamate 
• 3430-27-1 3-amino-4-methylpyridine 
• 1204176-45-3 methyl-(4-methylpiperidin-3-yI)carbamate 
• 923036-25-3 (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-2-chloro-N-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine 

Downstream Products

• 477600-74-1 tert-butyl (3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate 
• 1259404-17-5 tasocitinib 
• 540737-29-9 Tofacitinib citrate 
• 540737-29-9 tofacitinib hemi-citrate 
• 1616761-00-2 3-[(3R,4R)-3-({2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl}(methyl)amino)-4-methylpiperidin-1-yl]-3-oxopropanenitrile 

Relevant articles and documents

Tropsch process for cloth intermediate impurity, tofa for cloth impurity and its synthesis method, and Tropsch process for the cloth quality monitoring method

The invention provides a tofacitinib intermediate impurity, tofacitinib impurity and a synthetic method, and a tofacitinib quality monitoring method. The tofacitinib intermediate impurity has a chemical formula in a formula (I), and the tofacitinib impurity has a chemical formula in a formula (II). Through the provided tofacitinib intermediate impurity and the tofacitinib impurity, the invention provides a standard contrast product for monitoring and optimizing quality of N-methyl-N-((3R,4R)-4-methyl piperidine-3-group)-7H-pyrrolo[2,3-D]pyrimidine-4-amine (tofacitinib), and then performs qualitative and quantitative analysis on the tofacitinib intermediate and tofacitinib.